ERAS
Erasca IncKey Statistics
About Erasca Inc
Erasca Inc. is a pioneering biopharmaceutical firm dedicated to developing innovative targeted therapies for genetically defined cancers, targeting critical unmet needs in oncology. Utilizing its proprietary drug discovery platform, which integrates advanced genomics and precision medicine, the company aims to develop therapies that specifically address mutations driving cancer progression. With a promising pipeline of clinical-stage candidates focused on disrupting vital tumor growth pathways, Erasca is poised to enhance treatment standards and improve patient outcomes. Its commitment to advancing cancer care is further strengthened by strategic partnerships within the oncology research community, establishing Erasca as a leading force in the biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-130.68M |
| Operating Margin | 0.00% |
| Return on Equity | -69.90% |
| Return on Assets | -17.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.27 |
| Price-to-Book | 8.88 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $310.99M |
| Float | $207.89M |
| % Insiders | 10.66% |
| % Institutions | 92.96% |
Historical Volatility
Volatility is currently expanding